SHL logo

Sonic Healthcare Limited Stock Price

ASX:SHL Community·AU$9.6b Market Cap
  • 4 Narratives written by author
  • 4 Comments on narratives written by author
  • 129 Fair Values set on narratives written by author

SHL Share Price Performance

AU$19.34
-7.05 (-26.71%)
AU$30.00
Fair Value
AU$19.34
-7.05 (-26.71%)
35.5% undervalued intrinsic discount
AU$30.00
Fair Value
Price AU$19.34
Choppy AU$30.00
AnalystConsensusTarget AU$24.78
AnalystHighTarget AU$33.30

SHL Community Narratives

Fair Value
·
Fair Value AU$30 35.5% undervalued intrinsic discount

Sonic Healthcare Is Priced for Yesterday. Its AI Is Built for Tomorrow.

1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
·
Fair Value AU$24.78 21.9% undervalued intrinsic discount

Digital Pathology And Global Expansion Will Define Healthcare

1users have liked this narrative
4users have commented on this narrative
64users have followed this narrative
·
Fair Value AU$33.3 41.9% undervalued intrinsic discount

Radiology And Genetics Demand Will Transform This Diagnostics Consolidator Over The Next Decade

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AU$33.3
41.9% undervalued intrinsic discount
Revenue
9.64% p.a.
Profit Margin
7.26%
Future PE
21.02x
Price in 2029
AU$40.42
AU$23
15.9% undervalued intrinsic discount
Revenue
8.06% p.a.
Profit Margin
5.71%
Future PE
19.3x
Price in 2029
AU$27.92

Trending Discussion

Updated Narratives

SHL logo

Sonic Healthcare Is Priced for Yesterday. Its AI Is Built for Tomorrow.

Fair Value: AU$30 35.5% undervalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
SHL logo

SHL: Companion Diagnostics Partnership And Dividend Are Expected To Support Re Rating

Fair Value: AU$24.78 21.9% undervalued intrinsic discount
64 users have set this as their fair value
4 users have commented on this narrative
0 users have liked this narrative
SHL logo

Radiology And Genetics Demand Will Transform This Diagnostics Consolidator Over The Next Decade

Fair Value: AU$33.3 41.9% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued average dividend payer.

2 Risks
3 Rewards

Sonic Healthcare Limited Key Details

AU$10.4b

Revenue

AU$7.0b

Cost of Revenue

AU$3.4b

Gross Profit

AU$2.9b

Other Expenses

AU$539.4m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
1.09
32.84%
5.18%
47.6%
View Full Analysis

About SHL

Founded
1934
Employees
45000
CEO
James Newcombe
WebsiteView website
www.sonichealthcare.com

Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It also offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, general practice IT solutions, and community-based healthcare services, as well as clinical trials services. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.

Recent SHL News & Updates

Narrative Update Jun 04

SHL: Companion Diagnostics Partnership And Dividend Are Expected To Support Re Rating

Analysts have trimmed their price target for Sonic Healthcare by A$0.20 to reflect slightly adjusted assumptions around fair value, discount rate, revenue growth, profit margin and future P/E, while keeping the overall thesis broadly intact. What's in the News CellCarta and Sonic Healthcare USA have entered into a partnership to commercialize companion diagnostics through Sonic Healthcare's clinical laboratory network, with a focus on oncology, autoimmune disease and other precision medicine settings.
Narrative Update May 12

SHL: Upcoming A$0.45 Dividend Will Support Future Re Rating

Analysts have nudged their price target for Sonic Healthcare slightly lower to about A$24.98 from around A$25.26. The revision reflects updated assumptions for a higher discount rate, a modestly different revenue growth outlook, a steady profit margin profile and a slightly higher future P/E multiple.

Recent updates

No updates